The majority of breast cancer patients present with early-stage (91%), estrogen receptor (ER) positive disease (~ 75%), and/or no lymph node involvement (~ 65%) at diagnosis, which also contribute to the overall favorable prognosis [3–5]. This evidence concerns the gene ESR1 and breast cancer.